ArticleBrain : a journal of neurology2023
Assessment and prediction of glioblastoma therapy response: challenges and opportunities.
Article in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 58 citations in OpenAlex.
- The novel [RSC advances · 2026Article
- GBM-Dx SIGNAL: Blood transcriptomics complementing neuroimaging to differentiate glioblastoma recurrence from treatment effects.Genes & diseases · 2026Article
- Article
- Predictive value of apparent diffusion coefficient, plasma levels of placental growth factor and glial fibrillary acidic protein, and their combinations for patients with recurrent glioblastoma.Discover oncology · 2026Article
- Review
- Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma.Journal of Korean medical science · 2026Article
- Prognostic determinants and predictive modeling in higher-grade glioma patients receiving radiotherapy: a retrospective SEER-based study.Scientific reports · 2026Article
- Low-dose TNF-α drives malignant progression and lipid metabolism in glioblastoma through the TRAF2-FASN axis.Cell death discovery · 2026Article
- Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.Discover oncology · 2026Review
- Molecular Signatures and Network Alterations Underlying GBM Progression and Recurrence.Medicina (Kaunas, Lithuania) · 2026Article
- Tissue-type Differences in Focused Ultrasound and Microbubble-mediated Drug Delivery to the Brain Exist at Vessel Level.Theranostics · 2026Article
- A spatiotemporal state-inference framework for adaptive immunotherapy in glioblastoma.Frontiers in oncology · 2026Review
- Clinical and genetic determinants of glioblastoma survival: a retrospective study.Frontiers in molecular neuroscience · 2026Article
- ATP release mediated by TRPM3 enhances invasion in glioblastoma.Animal cells and systems · 2026Article
- Coupling proteostasis andTheranostics · 2026Article
- Single-Cell Transcriptome Atlas Reveals the Underlying Mechanism of Kynurenic Acid in the Regulation of Tumor Immune Microenvironment in Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An unsupervised tool for biomarker discovery and cancer subtyping applied to glioblastoma.BioData mining · 2025Article
- Recruiting T-cells toward the brain for enhanced glioblastoma chemo-immunotherapy efficacy by co-delivery of cytokines and temozolomide via ultrasound-gated redox-responsive extracellular vesicles.Journal of nanobiotechnology · 2025Article
- Investigating the impact of MCTP2 on immune suppression and drug resistance in glioblastoma.Functional & integrative genomics · 2025Article
- Deep Neural Network-Based Risk Prediction of Glioblastoma Multiforme Recurrence.Journal of molecular neuroscience : MN · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Glioblastoma is the most aggressive type of primary adult brain tumour. The median survival of patients with glioblastoma remains approximately 15 months, and the 5-year survival rate is <10%. Current treatment options are limited, and the standard of care has remained relatively constant since 2011. Over the last decade, a range of different treatment regimens have been investigated with very limited success. Tumour recurrence is almost inevitable with the current treatment strategies, as glioblastoma tumours are highly heterogeneous and invasive. Additionally, another challenging issue facing patients with glioblastoma is how to distinguish between tumour progression and treatment effects, especially when relying on routine diagnostic imaging techniques in the clinic. The specificity of routine imaging for identifying tumour progression early or in a timely manner is poor due to the appearance similarity of post-treatment effects. Here, we concisely describe the current status and challenges in the assessment and early prediction of therapy response and the early detection of tumour progression or recurrence. We also summarize and discuss studies of advanced approaches such as quantitative imaging, liquid biomarker discovery and machine intelligence that hold exceptional potential to aid in the therapy monitoring of this malignancy and early prediction of therapy response, which may decisively transform the conventional detection methods in the era of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.